Product Description: d-(RYTVELA) is a specific inhibitor of human thymocyte proliferation with an IC50 of 1 nM. d-(RYTVELA) inhibits IL-1–induced signaling pathways[1].
Applications: COVID-19-immunoregulation
Formula: C38H62N10O12
References: [1]Tiffany Habelrih, et al. Pharmacodynamic characterization of rytvela, a novel allosteric anti-inflammatory therapeutic, to prevent preterm birth and improve fetal and neonatal outcomes. Am J Obstet Gynecol. 2023, 228, 4.
CAS Number: 868844-53-5
Molecular Weight: 850.96
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related